Royalty Pharma (RPRX) Retained Earnings (2020 - 2026)
Royalty Pharma (RPRX) posted Retained Earnings of $2.5 billion for Q1 2026, down 39.19% sequentially from $4.1 billion in Q4 2025, and down 40.46% YoY from $4.2 billion in Q1 2025.
Royalty Pharma (RPRX) Retained Earnings (2020 - 2026) Analysis & Trends
Royalty Pharma has reported Retained Earnings for 7 years, with the latest figure at $2.5 billion in Q1 2026.
- Quarterly Retained Earnings fell 40.46% year-over-year to $2.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 billion (down 40.46% YoY) and the FY2025 annual result came in at $4.1 billion, up 44.89% from the prior year.
- Retained Earnings eased to $2.5 billion in Q1 2026 per RPRX's latest filing, from $4.1 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $4.2 billion in Q1 2025 and troughed at $12.3 million in Q1 2022.
- A 5-year average of $3.1 billion and a median of $3.6 billion in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings tumbled 58.22% in 2022, then surged 17916.99% in 2023.
- Over 5 years, Retained Earnings stood at $3.7 billion in 2022, then increased by 9.42% to $4.0 billion in 2023, then retreated by 29.06% to $2.8 billion in 2024, then soared by 44.89% to $4.1 billion in 2025, then sank by 39.19% to $2.5 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $2.5 billion, $4.1 billion, and $4.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.38 Bn |
| Mar 31, 2026 | 2.51 Bn |
| Dec 31, 2025 | 4.12 Bn |
| Sep 30, 2025 | 4.11 Bn |
| Jun 30, 2025 | 2.22 Bn |
| Mar 31, 2025 | 4.21 Bn |
| Dec 31, 2024 | 2.85 Bn |
| Sep 30, 2024 | 2.76 Bn |
| Jun 30, 2024 | 4.10 Bn |
| Mar 31, 2024 | 4.07 Bn |
| Dec 31, 2023 | 4.01 Bn |
| Sep 30, 2023 | 2.13 Bn |
| Jun 30, 2023 | 2.25 Bn |
| Mar 31, 2023 | 2.22 Bn |
| Dec 31, 2022 | 3.67 Bn |
| Sep 30, 2022 | 3.63 Bn |
| Jun 30, 2022 | 3.57 Bn |
| Mar 31, 2022 | 12.30 Mn |
| Dec 31, 2021 | 2.26 Bn |
| Sep 30, 2021 | 2.32 Bn |